• Incyte released updated Phase 1 data at EHA 2026 for INCA033989, a mutant CALR-targeted antibody in myelofibrosis and essential thrombocythemia.
• Trials showed rapid, durable clinical improvements across key disease measures, with molecular responses that supported a potential disease-modifying profile.
• Safety was described as manageable, with most patients remaining on therapy across both studies.
• A pivotal Phase 3 study in essential thrombocythemia is set to start in mid-2026, with regulators engaged on a pivotal myelofibrosis program.
• The FDA granted Breakthrough Therapy designation in November 2025 for Type 1 CALR-mutated essential thrombocythemia after prior cytoreductive therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260613021335) on June 13, 2026, and is solely responsible for the information contained therein.